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Summary
The randomized, double-blind, double-dummy, phase 3b RELIEF trial eval-
uated polycythaemia vera (PV)-related symptoms in patients who were well
controlled with a stable dose of hydroxycarbamide (also termed hydrox-
yurea) but reported PV-related symptoms. Patients were randomized 1:1 to
ruxolitinib 10 mg BID (n = 54) or hydroxycarbamide (prerandomization
dose/schedule; n = 56); crossover to ruxolitinib was permitted after Week
16. The primary endpoint, ≥50% improvement from baseline in myelopro-
liferative neoplasm -symptom assessment form total symptom score cyto-
kine symptom cluster (TSS-C; sum of tiredness, itching, muscle aches,
night sweats, and sweats while awake) at Week 16, was achieved by 434%
vs. 296% of ruxolitinib- and hydroxycarbamide-treated patients, respec-
tively (odds ratio, 182; 95% confidence interval, 082–404; P = 0139).
The primary endpoint was achieved by 34% of a subgroup who maintained
their hydroxycarbamide dose from baseline to Weeks 13–16. In a post hoc
analysis, the primary endpoint was achieved by more patients with stable
screening-to-baseline TSS-C scores (ratio ≤ 2) receiving ruxolitinib than
hydroxycarbamide (474% vs. 250%; P = 00346). Ruxolitinib treatment
after unblinding was associated with continued symptom score improve-
ments. Adverse events were primarily grades 1/2 with no unexpected safety
signals. Ruxolitinib was associated with a nonsignificant trend towards
improved PV-related symptoms versus hydroxycarbamide, although an
unexpectedly large proportion of patients who maintained their hydroxy-
carbamide dose reported symptom improvement.
Keywords: polycythaemia vera, quality of life, signs and symptoms, Janus
kinase, hydroxycarbamide.
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Polycythaemia vera (PV) is a Philadelphia-negative myelo-
proliferative neoplasm (MPN) characterized by primary
erythrocytosis and deregulated Janus kinase/signal trans-
ducer and activator of transcription signalling (Vannucchi,
2014). Most patients with PV experience a broad symptom
burden that may include fatigue/tiredness, itching, muscle
aches and sweating (Emanuel et al, 2012; Vannucchi et al,
2015). The biomolecular underpinnings of PV-related
symptoms have not been fully elucidated. However, ele-
vated serum inflammatory cytokine levels have been
reported in MPN patients (Barbui et al, 2011; Vaidya et al,
2012; Pourcelot et al, 2014) and may contribute to the
severity of symptoms, including itching and night sweats
(Tefferi et al, 2011; Squires et al, 2013). Other common
aspects of the PV disease state, including blood hypervis-
cosity (Barbui et al, 2013) and splenomegaly (Mesa et al,
2007), may also play a role in the symptom profile of
some patients. The overall PV-related symptom burden, as
measured by the MPN Symptom Assessment Form total
symptom score (MPN-SAF TSS), as well as the severity of
individual symptoms, including fatigue (Emanuel et al,
2012; Abelsson et al, 2013) and itching (Siegel et al, 2013),
have been associated with reduced quality of life in
patients with PV.
Polycythaemia vera is adequately managed with phle-
botomy and low-dose aspirin in some patients (Marchioli
et al, 2013), but many require additional therapy to achieve
their treatment goals. The most common cytoreductive treat-
ment is hydroxycarbamide (HC, also termed hydroxyurea)
(Vannucchi, 2014), which is effective for controlling blood
cell counts in some patients (Najean & Rain, 1997; Alvarez-
Larran et al, 2012). However, PV-related symptoms are gen-
erally not well controlled with HC treatment (Johansson
et al, 2012; Scherber et al, 2012).
In the phase 3 RESPONSE trial, ruxolitinib treatment was
superior to best available therapy for the control of haemat-
ocrit without phlebotomy and management of splenomegaly
in patients with PV who had an inadequate response to, or
were intolerant of, HC (Vannucchi et al, 2015). Ruxolitinib
treatment was also associated with improvements in PV-
related symptoms (Vannucchi et al, 2015; Mesa et al, 2016).
We therefore conducted a randomized, double-dummy, pla-
cebo-controlled phase 3b trial (RELIEF) in patients who had
been receiving a stable dose of HC and were generally well
controlled but still reported disease-associated symptoms.
The primary objective of the trial was to compare the change
in PV-related symptom burden in patients continuing their
HC therapy with those switching to ruxolitinib.
Methods
Patients
Eligible patients were ≥18 years of age, diagnosed with PV
according to the World Health Organization criteria (Tefferi
& Vardiman, 2008), treated with HC monotherapy for
≥12 weeks before enrolment, had received a stable dose of
HC for ≥4 weeks before enrolment and had cytokine-related
symptoms defined as a score ≥8 (maximum, 50) on the
MPN-SAF TSS cytokine symptom cluster (TSS-C) (Vannuc-
chi et al, 2015). The TSS-C is the sum of individual scores
for tiredness, itching, muscle aches, night sweats and sweats
while awake, each rated on a scale of 0 (absent) to 10 (worst
imaginable). The requirement for TSS-C score ≥8 (i.e, mean
score ≥16 on each of the 5 individual components) was
implemented to ensure that patients had an adequate symp-
tom score at baseline to assess meaningful changes in the pri-
mary endpoint. The TSS clusters were identified using an
empirical statistical factor analysis of baseline MPN-SAF
scores from the phase 3 RESPONSE trial (Vannucchi et al,
2015). This analysis divided the 14 individual MPN-SAF
symptoms into 3 symptom clusters independent of presumed
pathophysiological mechanisms. From a clinical perspective,
the 3 symptom clusters agreed well with 3 presumptive
pathophysiological mechanisms associated with PV-related
symptoms (cytokines, hyperviscosity and splenomegaly). Eli-
gible patients had ≤2 phlebotomies in the 6 months before
screening or no palpable splenomegaly; therefore, the TSS-C
was chosen to define patient eligibility and the primary end-
point. Eligible patients also had haematocrit values between
35% and 48% before randomization; had recovered from all
phlebotomy-associated adverse events, with ≥1 week elapsed
between the last phlebotomy and baseline; and had an East-
ern Cooperative Oncology Group performance status of 0–2
at baseline. Patients with inadequate liver or renal function,
platelet count <100 9 109/l, neutrophil count <1 9 109/l, or
peripheral blood blast count >0% at screening were not eligi-
ble.
Study design
RELIEF (ClinicalTrials.gov identifier, NCT01632904) was a
randomized, multicentre, double-blind, double-dummy,
phase 3b clinical trial evaluating ruxolitinib versus HC in
patients with PV reporting disease-related symptoms while
receiving a stable dose of HC (Fig 1). Eligible patients were
randomized 1:1 to receive ruxolitinib (10 mg twice daily)
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plus HC placebo or HC (prerandomization dose and sched-
ule) plus ruxolitinib placebo.
Treatment dose modifications were permitted for safety
and efficacy and to optimize response for each patient. HC
dose modifications were per investigator judgment; increases
to a dose that was not previously tolerated were not permitted.
Ruxolitinib dose increases were permitted for patients demon-
strating both inadequate efficacy (defined as ≥1 of the follow-
ing: haematocrit ≥45% or >40% and ≥3 percentage points
above baseline; white blood cell or platelet count above the
upper limit of normal; reduction from baseline in palpable
spleen length of <25% at Week 4 and <50% at Week 8; or
minimal improvement, no change or worsening on the Patient
Global Impression of Change [PGIC]) and adequate haemato-
logical parameters (defined as platelet count ≥140 9 109/l,
haemoglobin ≥120 g/l, and absolute neutrophil count
≥15 9 109/l). Blood counts were assessed at Day 1 and every
4 weeks during the blinded treatment phase, and every
12 weeks starting at Week 24 during the open-label treatment
phase. For patients who crossed over to ruxolitinib, blood
counts were also assessed at 4 and 8 weeks after crossover.
Ruxolitinib dose increase was also permitted after a prior dose
reduction for safety. Ruxolitinib dose increases were permitted
in the absence of select grade 1 cytopaenias; dose reductions
or interruptions were required for select grade ≥2 cytopaenias.
Dose modifications were made to the study drug and placebo
to ensure continued blinding, where applicable.
After the 16-week blinded treatment phase, patients in
either treatment arm with adequate haematological parameters
(i.e, platelet count ≥100 9 109/l, neutrophil count ≥1 9 109/l
and haemoglobin ≥120 g/l) were eligible to receive open-label
ruxolitinib until study completion at Week 48.
Endpoints
The primary endpoint was the proportion of patients with
≥50% reduction (improvement) from baseline in TSS-C at
Week 16. Secondary endpoints included the proportion of
patients with ≥50% reduction (improvement) from baseline
in individual TSS-C symptom severity scores at Week 16 and
safety parameters, including nonhaematological and
haematological adverse events. Exploratory endpoints
included median changes from baseline in TSS-C individual
symptom severity scores at Week 16 and the proportion of
patients reporting treatment-related improvements in PV
symptoms at Week 16 using the PGIC (Dworkin et al, 2005).
Assessments
Polycythaemia verarelated symptom severity was assessed
with the MPN-SAF questionnaire once during screening
between Days 28 and 7 (using a 7-day recall), daily dur-
ing the baseline phase between Days 7 and 1, and daily
starting at randomization and continuing until the end of
treatment. Baseline score was defined as the average score
during the 7 days before randomization (a minimum of
4 days of TSS-C scores was required before randomization).
The Week 16 TSS-C score was defined as the average over
the last 28 days before the Week 16 visit. Week 16 scores
were considered missing if there were <20 days of data
recorded before the Week 16 visit.
The single-item PGIC instrument asks patients to grade
changes in their PV-related symptoms since starting study
treatment using the following response options: “very much
improved” to “much improved”, “minimally improved”, “no
change”, “minimally worse”, “much worse” and “very much
worse “(Dworkin et al, 2005). Patient responses on the PGIC
were captured at Weeks 4, 8, 12, and 16.
Safety
All adverse events, regardless of causality, were assessed
according to the National Cancer Institute. Common Termi-
nology Criteria for Adverse Events, version 30 (2016 http://
ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf). Haematological adverse events were evalu-
ated based on laboratory values.
Statistical analyses
A previous study of patients with primary myelofibrosis
(MF), post-PV MF or post–essential thrombocythaemia-MF
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(Primary endpoint‡
and
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(Study termination)
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Fig 1. Study design. HC, hydroxycarbamide.
*All patients received low-dose aspirin unless
contraindicated. †Patients randomized to HC
plus placebo were eligible to cross over after
Week 16 to receive open-label ruxolitinib if
safety criteria were met. ‡The primary endpoint
was the proportion of patients who achieved
≥50% improvement in Myeloproliferative Neo-
plasm Symptom Assessment Form total symp-
tom score cytokine symptom cluster at Week
16.
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found that approximately 46% who received ruxolitinib and
5% who received placebo experienced a ≥50% reduction (im-
provement) in total symptom score at Week 24 (Verstovsek
et al, 2012). As such, the sample size of the current study
was selected based on an assumption that ≥35% of patients
in the ruxolitinib arm and 75% of patients in the HC arm
would achieve a ≥50% reduction (improvement) in TSS-C at
Week 16. Based on this assumption, a sample size of 100
patients (n = 50 per treatment arm) would provide 90%
power (2-sided alpha, 005).
Efficacy endpoints were evaluated in the intent-to-treat
population, with the following exception: for analyses of
individual TSS-C symptom scores, patients were excluded if
scores were either missing at baseline or 0 at baseline and
Week 16; patients with a score of 0 at baseline and a score
>0 at Week 16 were considered nonresponders and included
in the analyses. The safety analysis set included all rando-
mized patients who received ≥1 dose of study treatment.
The primary endpoint was estimated with 95% confidence
intervals (CIs); the odds ratio (OR) and corresponding 95%
CIs were also calculated for the primary endpoint using the
Fisher exact test.
A post hoc subgroup analysis was performed to evaluate
the association between changes in TSS-C during the time
between screening and baseline (up to 3 weeks) and corre-
sponding changes in TSS-C at Week 16. The proportion of
patients achieving ≥50% improvement in TSS-C at Week 16
was calculated among patient subgroups with TSS-C
screening-to-baseline ratios ≤2 or >2; 95% CIs were calcu-
lated using the Clopper-Pearson exact method, and P values
were calculated using the chi-square test.
A second post hoc analysis evaluated the effect of treat-
ment dose modifications during the blinded treatment phase
on changes in TSS-C. The proportion of patients achieving
≥50% improvement in TSS-C at Week 16 was calculated
among those who required a dose reduction, maintained a
consistent dose, and required a dose increase from baseline
to Weeks 13 through 16. The coefficient of determination
was used to evaluate the correlation between individual
changes in study treatment dose from baseline to Weeks 13
through 16 and the percentage change in TSS-C.
Treatment adherence was assessed using pill counts
recorded by study site staff members and calculated for each
patient as the percentage of the intended dose (i.e, sum of
doses prescribed by the investigator) that was taken.
All other analyses were summarized by descriptive statis-
tics.
Results
Patient characteristics and treatment adherence
In total, 110 patients were randomized between 2 July 2012
and 27 March 27 2014 (ruxolitinib, n = 54; HC, n = 56;
Fig 2). Median age at baseline was similar between the treat-
ment arms (Table I), and most patients did not have baseline
Enrolled and randomly assigned
N = 110
Ruxolitinib, 10 mg twice daily
n = 54
Discontinued during blinded phase, n (%) 7 (13·0)
Adverse event* 4 (7·4)
Patient decision 3 (5·6)
HC, preenrolment schedule 
n = 56
Discontinued during blinded phase, n (%) 6 (10·7)
Subject decision 2 (3·6)
Adverse event† 1 (1·8)
Disease progression 1 (1·8)
Physician decision 1 (1·8)
Other 1 (1·8)
Still in blinded phase at data cut-off,‡ n (%) 9 (16·7) Still in blinded phase at data cut-off,‡ n (%) 11 (19·6)
Completed blinded phase but did not 
enter open-label phase, n (%)
3 (5·6) Completed blinded phase but did not 
enter open-label phase, n (%)
3 (5·4)
Crossed over to ruxolitinib in 
open-label phase, n (%)
36 (64·3)Continued on ruxolitinib in 
open-label phase, n (%)
35 (64·8)
Fig 2. Patient disposition. HC, hydroxycarbamide. *Arterial occlusive disease, blurred vision, diarrhoea, fatigue, increased platelet count, muscular
weakness, musculoskeletal and connective tissue disorders, pyrexia, unstable angina, upper abdominal pain, and urinary tract pain; >1 adverse
event could be the cause of discontinuation in a given patient. †Deep vein thrombosis. ‡Data cut-off for this analysis occurred when the last
patient completed the Week 16 visit. Patients were still in the blinded phase at data cut-off if the unblinding date was missing or occurred after
the cut-off date.
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white blood cell or platelet counts higher than European
LeukaemiaNet thresholds (Barosi et al, 2013) (white blood
cell count, 10 9 109/l; platelet count, 400 9 109/l). The
majority of patients in the ruxolitinib arm were women,
whereas the majority of patients in the HC arm were men. A
greater proportion of patients in the ruxolitinib arm had a
history of thromboembolic events (ruxolitinib, 333%; HC,
214%). The median treatment adherence rate was 983% in
the ruxolitinib arm and 977% in the HC arm. A total of 35
patients randomized to the ruxolitinib arm and 36 patients
randomized to the HC arm began open-label treatment with
ruxolitinib after completing the double-blind phase (Fig 2).
Efficacy
The primary endpoint, ≥50% improvement from baseline in
TSS-C at Week 16, was achieved by 434% of patients in the
ruxolitinib arm and 296% in the HC arm; however, the dif-
ference between arms was not statistically significant (OR,
182; 95% CI, 082–404; P = 0139; Table II). There was a
trend towards a greater proportion of patients in the
ruxolitinib arm achieving ≥50% improvement from baseline
in the individual TSS-C symptoms compared with the HC
arm; however, only the difference for itching was statistically
significant (OR, 251; 95% CI, 110–571; P = 0027; Table II).
In addition, there was a trend towards greater improvement
in the median percentage change from baseline in the individ-
ual TSS-C symptoms in favour of ruxolitinib at Week 16
(Table III). Treatment with ruxolitinib during the unblinded
treatment phase (randomized ruxolitinib and crossover) was
associated with continued benefit based on the median per-
centage change from baseline in TSS-C and individual TSS-C
symptom severity scores at 24 and 48 weeks after initiation of
ruxolitinib therapy (Table III). The proportion of patients
who achieved a ≥50% improvement in the MPN-SAF TSS or
individual hyperviscosity- or splenomegaly-related symptoms
was similar between the treatment arms (data not shown), as
expected for this PV patient population with generally well-
controlled haematocrit and/or no splenomegaly.
Some patients reported large changes in symptom severity
between screening and baseline, with TSS-C symptom scores
at least twice as severe at screening compared with baseline
in 15/53 (283%) evaluable patients in the ruxolitinib arm
and 10/54 (185%) evaluable patients in the HC arm. There-
fore, a post hoc subgroup analysis was performed among
patients with relatively stable TSS-C scores between screening
and baseline (i.e, screening-to-baseline TSS-C ratio ≤2).
Among these patients, a significantly greater proportion in
the ruxolitinib arm compared with the HC arm achieved a
≥50% improvement from baseline in TSS-C at Week 16
(ruxolitinib, 474%; HC, 250%; P = 00346; Table IV). The
proportion of patients who achieved a ≥50% reduction from
baseline in TSS-C at Week 16 was not significantly different
between treatment arms for patients with a screening-to-
baseline TSS-C ratio >2.
Table I. Baseline characteristics.
Ruxolitinib
(n = 54)
HC
(n = 56)
Median (range) age, years 64 (36–87) 66 (19–85)
Male, n (%) 24 (444) 34 (607)
Race, n (%)
White 53 (981) 56 (100)
Asian 1 (19) 0
Median (range) time since
PV diagnosis, months
585 (76–3950) 624 (35–2775)
History of thromboembolic
events, n (%)
18 (333) 12 (214)
Mean (SD) JAK2V617F
allele burden, %
477 (290) 479 (302)
ECOG performance status, n (%)
0 25 (463) 32 (571)
1 27 (500) 22 (393)
2 2 (37) 2 (36)
Median (range) palpable
spleen length below the
costal margin, cm
00 (00–130) 00 (00–90)*
Mean (SD) WBC count,
9109/l
90 (55) 106 (98)
≤10, n (%) 39 (722) 39 (696)
>10–15, n (%) 9 (167) 9 (161)
>15, n (%) 6 (111) 8 (143)
Mean (SD) platelet count,
9109/l
3574 (1454) 3482 (1893)
≤400, n (%) 35 (648) 35 (625)
>400–600, n (%) 17 (315) 16 (286)
>600, n (%) 2 (37) 5 (89)
Mean (SD) haematocrit, % 421 (34) 437 (34)
<40, n (%) 15 (278) 8 (143)
40–45, n (%) 27 (500) 27 (482)
>45, n (%) 12 (222) 21 (375)
Mean (SD) MPN-SAF
TSS-C score†
167 (98) 180 (100)
Tiredness 46 (25) 52 (27)
Itching 36 (29) 40 (27)
Muscle aches 33 (26) 37 (27)
Night sweats 28 (26) 26 (23)
Sweats while awake 24 (23) 25 (27)
PV treatment history, n (%)
HC 54 (100) 56 (100)
Interferon 2 (37) 4 (71)
Anagrelide 4 (74) 1 (18)
Pipobroman 1 (19) 0
Cladribine 0 1 (18)
Investigational drug 0 1 (18)
ECOG, Eastern Cooperative Oncology Group; HC, hydroxycarbamide;
MPN-SAF TSS-C, Myeloproliferative Neoplasm Symptom Assessment
Form total symptom score cytokine symptom cluster; PV, poly-
cythaemia vera; SD, standard deviation; WBC, white blood cell.
*n = 53.
†The TSS-C is the sum of the individual symptom scores for tired-
ness, itching, muscle aches, night sweats, and sweating while awake
(maximum, 50). Individual symptom scores were each rated on a
scale of 0 (absent) to 10 (worst imaginable).
R. Mesa et al
80 ª 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2017, 176, 76–85
Dose modifications occurred in 24 patients in the ruxoli-
tinib arm (reduction, n = 11; increase, n = 13) and 21
patients in the HC arm (reduction, n = 9; increase, n = 12).
There was no statistically significant correlation between
changes in treatment dose from baseline to Weeks 13
through 16 and the percentage change in TSS-C in either
treatment arm (coefficient of determination: ruxolitinib arm,
0018; HC arm, 0030). Among patients who continued to
receive the same HC dose between baseline and Weeks 13–
16, 343% achieved ≥50% improvement in TSS-C (Table V).
Using the PGIC, a greater proportion of patients in the
ruxolitinib arm reported that their PV-related symptoms
were “very much improved” or “much improved” at Week
16 as a result of treatment (ruxolitinib, 481%; HC, 304%;
OR, 213; 95% CI, 098–465), whereas patients in the HC
arm were more likely to describe their symptoms as “mini-
mally improved” or “no change” (ruxolitinib, 333%; HC,
554%). The proportions of patients who reported each PGIC
response option are presented in Fig 3.
Safety
Adverse events during blinded treatment are summarized in
Table VI. Events were primarily grades 1 or 2 in both treat-
ment arms. The most common nonhaematological adverse
events in the ruxolitinib arm included fatigue, headache, and
dizziness. Diarrhoea, constipation, fatigue, and pruritus were
the most common nonhaematological adverse events in the
HC arm. Anaemia and thrombocytopaenia were mainly
grades 1 or 2 in each treatment arm. Five patients in the
ruxolitinib arm and 4 patients in the HC arm experienced
serious adverse events during blinded treatment: thromboem-
bolic events occurred in 2 patients in the ruxolitinib arm and
2 patients in the HC arm.
Herpes zoster infection was observed in 1 patient in the
ruxolitinib arm during blinded treatment; no patients
received prophylaxis treatment for herpes zoster infection
before or during the trial. During blinded treatment, squa-
mous cell carcinoma was observed in 1 patient in the ruxoli-
tinib arm, and no patients had disease transformation to MF
or acute myeloid leukaemia (AML). After completion of the
blinded treatment phase, 1 additional patient in the ruxoli-
tinib arm developed squamous cell carcinoma and 1 patient
in the ruxolitinib arm was diagnosed with disease
Table II. Proportion of patients with ≥50% improvement in
MPN-SAF TSS-C and individual symptoms at Week 16*.
Symptom, n/N†
(%) Ruxolitinib HC
P value
OR (95% CI)
Primary endpoint
TSS-C 23/53 (434) 16/54 (296) 0139
182 (082–404)
Individual symptoms
Tiredness 20/50 (400) 14/53 (264) 0143
186 (081–427)
Itching 26/48 (542) 16/50 (320) 0027
251 (110–571)
Muscle aches 18/47 (383) 15/49 (306) 0428
141 (060–328)
Night sweats 20/42 (476) 20/48 (417) 0571
127 (055–293)
Sweats while
awake
23/42 (548) 16/46 (348) 0059
227 (096–4038)
HC, hydroxycarbamide; OR, odds ratio; MPN-SAF TSS C, Myelo-
proliferative Neoplasm Symptom Assessment Form total symptom
score cytokine symptom cluster.
*For individual symptoms within the TSS C cluster, all patients with
a score >0 at baseline were included in the analysis. If the baseline
score was 0 and Week 16 score was >0, the patient was considered a
nonresponder. If the baseline and Week 16 scores were both 0, the
patient was excluded from the responder analysis.
†The denominator is the number of evaluable patients.
Table III. Median percentage change from baseline or crossover in MPN-SAF TSS-C and individual symptoms*.
Treatment duration
after baseline or
crossover, weeks†
Ruxolitinib
Ruxolitinib
crossover group HC
8 16 24 48 8 24 48 8 16
Median percentage change in symptom score, % (evaluable n)
TSS-C 412 (49) 503 (45) 478 (34) 819 (10) 451 (28) 177 (15) 531 (16) 306 (52) 302 (50)
Tiredness 228 (47) 395 (43) 378 (32) 870 (9) 239 (26) 72 (15) 375 (15) 207 (51) 279 (49)
Itching 680 (41) 680 (38) 692 (28) 921 (8) 618 (23) 356 (13) 647 (12) 284 (47) 313 (45)
Muscle aches 395 (44) 436 (41) 302 (31) 933 (9) 233 (23) 157 (13) 426 (14) 273 (46) 294 (45)
Night sweats 621 (37) 595 (33) 650 (24) 958 (8) 676 (18) 139 (13) 652 (9) 508 (42) 469 (41)
Sweats while awake 549 (39) 656 (36) 625 (27) 989 (8) 593 (14) 59 (10) 851 (8) 326 (40) 399 (39)
HC, hydroxycarbamide; MPN-SAF TSS-C, Myeloproliferative Neoplasm Symptom Assessment Form total symptom score cytokine symptom
cluster.
*All patients with a score >0 at baseline were included in the analysis.
†Treatment duration: (1) after baseline in the ruxolitinib and HC groups; (2) after crossover from HC to ruxolitinib in the ruxolitinib crossover
group.
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transformation to MF (Day 211, 24 days after the final dose
of ruxolitinib) and AML (Day 216, 29 days after the final
dose of ruxolitinib); no additional cases of herpes zoster
infection or nonmelanoma skin cancer were observed in
either treatment arm.
Four patients in the ruxolitinib arm and 1 patient in the
HC arm discontinued because of adverse events (Fig 2).
There were 2 deaths during the trial, both of which occurred
after completion of the blinded treatment phase; 1 patient
died from pneumonia after discontinuing HC but before
crossing over to ruxolitinib, and 1 patient randomized to
ruxolitinib died because of transformation to AML.
Discussion
This report of the RELIEF trial primary results indicates that
for patients with generally well-controlled PV receiving a
stable dose of HC, a change in treatment to ruxolitinib
monotherapy was associated with a positive trend in symp-
tom improvement compared with those continuing on HC,
although this trend was not statistically significant. At Week
16, median changes from baseline in all individual TSS-C
symptom scores favoured ruxolitinib and were still improv-
ing at Week 48. Itching was the symptom with the most pro-
nounced improvements observed with ruxolitinib at Week
16. Patients who crossed over to ruxolitinib after randomiza-
tion to HC experienced improvements in all individual TSS-
C symptom scores within 8 weeks of ruxolitinib treatment;
symptom scores stabilised or continued to improve with
48 weeks of treatment. However, data on long-term and
crossover treatment with ruxolitinib were limited by small
patient populations. Patient-reported improvements in symp-
tom severity were better with ruxolitinib compared with HC;
a greater proportion of patients receiving ruxolitinib reported
that their symptoms were “very much improved” or “much
improved”.
This randomized clinical trial is the first in patients with
MPNs to evaluate symptoms as the primary endpoint and
provides important insights into how best to design future
trials in this setting with regard to statistical power and the
impact of perceived eligibility criteria. An important limita-
tion of this study was that it did not anticipate, and therefore
underestimated, the relatively high proportion of patients
who achieved the primary endpoint in the HC arm,
Table IV. Proportion of patients achieving ≥50% improvement in
MPN-SAF TSS-C at Week 16, by screening-to-baseline TSS-C ratio*.
Ruxolitinib
(n = 53†)
HC
(n = 54†)
Screening-to-baseline
TSS-C ratio ≤2, n
38 44
Response rate, % (95% CI) 474 (310–642) 250 (132–403)
P value 00346
Screening-to-baseline
TSS-C ratio >2, n
15 10
Response rate, % (95% CI) 333 (118–616) 500 (187–813)
P value 04422
HC, hydroxycarbamide; MPN-SAF TSS-C, Myeloproliferative Neo-
plasm Symptom Assessment Form total symptom score cytokine
symptom cluster.
*The time between screening and baseline was up to 3 weeks for all
patients except 1 in the HC arm (7 weeks).
†One patient in the ruxolitinib arm and 2 patients in the HC arm
were excluded because TSS-C at baseline and Week 16 were 0 or
missing.
Table V. Proportion of patients with ≥50% improvement in MPN-
SAF TSS-C at Week 16, by change in dose between baseline and
Weeks 13–16.
Patients, n/N (%) Ruxolitinib (n = 54) HC (n = 56)
Dose reduction 2/11 (182) 0/9 (0)
Consistent dose 13/30 (433) 12/35 (343)
Dose increase 8/13 (615) 4/12 (333)
HC, hydroxycarbamide; MPN-SAF TSS-C, Myeloproliferative Neo-
plasm Symptom Assessment Form total symptom score cytokine
symptom cluster.
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Fig 3. Patient Global Impression of Change at
Week 16. *HC, hydroxycarbamide. Percentage
of patients with missing data: ruxolitinib,
130%; HC, 71%. *N is the number of patients
in each treatment arm; n is the number of
patients who selected each response option.
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including those who received a consistent HC dose from
baseline to Weeks 13 to 16 (34%). The reason for this find-
ing is unclear. Although compliance in a clinical trial may be
better than in clinical practice, this is an unlikely explanation
because previous findings in patients with PV suggest that
HC treatment is not associated with clinically relevant
improvements in symptoms (Johansson et al, 2012; Scherber
et al, 2012; Mesa et al, 2015; Geyer et al, 2016). However,
randomized controlled trial data addressing this question are
lacking. It is also possible that patients in RELIEF experi-
enced closer medical follow-up and better availability of sup-
portive measures that may not be typical of standard care
settings, which would suggest a potential for better patient
outcomes with improved supportive care. Some patients may
have entered the study with an expectation of symptomatic
relief, which may have contributed to a placebo effect. The
substantial difference between symptom scores at screening
(reported using a 1-week recall) and baseline (average of
daily reporting) suggests a possible over-reporting bias for
some patients at screening, which may have been affected by
patient awareness of the eligibility requirement for pro-
nounced symptoms. In support of this concept, a post hoc
subgroup analysis demonstrated that patients with relatively
stable TSS-C between screening and baseline were signifi-
cantly more likely to achieve ≥50% improvement in TSS-C
at Week 16 with ruxolitinib versus HC. These data suggest
that the lower than expected baseline scores for some
patients may have compromised the ability to observe clini-
cally relevant changes from baseline during study treatment.
Gender differences in treatment response and symptom
assessment may also have affected study results; a smaller
proportion of patients in the ruxolitinib arm were male com-
pared with the HC arm. Finally, the study was not designed
or powered to evaluate measures other than symptoms, pre-
cluding evaluation of other clinical outcomes including
changes in blood counts and spleen volume.
Previous phase 3 studies suggest that ruxolitinib improves
symptoms compared with best available therapy (including
HC) in patients with MF or PV. In patients with MF, there
is evidence of meaningful improvement in symptoms with
ruxolitinib versus placebo, as evaluated by the MPN-SAF
(Mesa et al, 2013), and versus best available therapy (47%
receiving HC) using the European Organisation for Research
and Treatment of Cancer Quality of Life Question-
naireCore 30 (EORTC QLQ-C30) (Harrison et al, 2012).
Similar findings were observed in the randomized, open-
label, multicentre, phase 3 RESPONSE trial, which evaluated
ruxolitinib versus best available therapy (59% receiving HC)
in patients with PV who were intolerant of or resistant to
HC (Vannucchi et al, 2015). Exploratory analyses of changes
in symptom severity from baseline to Week 32 demonstrated
that ruxolitinib was associated with greater improvements in
items on the MPN-SAF, EORTC QLQ-C30, and Pruritus
Symptom Impact Scale (Vannucchi et al, 2015) compared
with lesser improvements or worsening symptoms/quality of
life with best available therapy. There were several important
differences between the patient populations included in
RESPONSE and RELIEF that may explain why the ruxoli-
tinib symptom results were not in agreement between these
studies. RESPONSE included a larger patient population
Table VI. Adverse events during the blinded phase.
Adverse event
Ruxolitinib (n = 54) HC (n = 56)
All Grades* Grade 3/4* All Grades* Grade 3/4*
Nonhaematological,† n (%)
Fatigue 11 (204) 1 (19) 6 (107) 1 (18)
Headache 9 (167) 0 3 (54) 0
Dizziness 7 (130) 0 5 (89) 0
Nausea 6 (111) 0 3 (54) 0
Pruritus 6 (111) 0 6 (107) 0
Rash 6 (111) 0 0 0
Diarrhoea 5 (93) 0 11 (196) 0
Constipation 4 (74) 0 7 (125) 0
Haematological,‡ n/N (%)
Anaemia 20/54 (370) 0 13/56 (232) 1/55 (18)
Thrombocytopaenia 5/54 (93) 0 15/56 (268) 1/55 (18)
Leucopaenia 6/54 (111) 1/54 (19) 13/56 (232) 1/55 (18)
Lymphopaenia 10/54 (185) 3/50 (60) 20/56 (357) 2/49 (41)
Neutropaenia 2/54 (37) 2/54 (37) 7/56 (125) 1/54 (19)
HC, hydroxycarbamide.
*Per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 30.
†Adverse events reported by >10% of patients in either arm.
‡New or worsening haematology laboratory values; n indicates the number of patients with abnormal laboratory values, N indicates the number
of evaluable patients (patients were evaluable for new or worsening grade 3/4 haematology laboratory values if post-baseline data were available
and data were missing at baseline or the severity at baseline was grade ≤2).
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(N = 222) with a more severe disease state compared with
RELIEF (N = 110). In RESPONSE, patients were required to
have splenomegaly at baseline and to be intolerant of or
resistant to HC. In contrast, RELIEF patients were generally
well controlled with HC but experienced persistent PV-
related symptoms. At baseline, patients randomized to rux-
olitinib in RESPONSE versus RELIEF had a longer median
duration of PV (984 months vs. 585 months), longer med-
ian palpable spleen length (70 cm vs. 00 cm), higher mean
blood counts (white blood cell, 176 9 109/l vs. 90 9 109/l;
platelet, 4845 9 109/l vs. 3574 9 109/l), and a higher mean
JAK2V617F allele burden (762% vs. 290%) (Vannucchi
et al, 2015).
The safety and tolerability profile of ruxolitinib observed in
RELIEF was consistent with that reported in previous phase 2
and 3 studies of patients intolerant of or resistant to HC (Ver-
stovsek et al, 2014; Vannucchi et al, 2015). Adverse events
were generally grades 1 or 2, with few patients (74%) discon-
tinuing ruxolitinib treatment because of an adverse event.
In conclusion, treatment with ruxolitinib was associated
with a nonsignificant trend towards improvements in TSS-C
compared with HC in patients who had generally well-con-
trolled PV with a stable dose of HC but still reported dis-
ease-associated symptoms. A statistically significant
improvement in itching was observed with ruxolitinib com-
pared with HC, trends towards improvements with ruxoli-
tinib were observed in all other symptoms, and patients with
stable screening-to-baseline TSS-C were less likely to report
responses to treatment with HC. The large proportion of
patients achieving the primary endpoint while continuing to
receive a stable HC dose was unexpected and may have
implications for the design of future clinical trials.
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